In a patient with bipolar I disorder who is stable on quetiapine, lithium, and lamotrigine and is also taking escitalopram and bupropion, which antidepressant should be tapered first?

Taper Escitalopram First

In a stable patient with bipolar I disorder on quetiapine, lithium, and lamotrigine who is also taking both escitalopram (an SSRI) and bupropion, escitalopram should be tapered first. This recommendation prioritizes minimizing the risk of mood destabilization and manic switch while maintaining adequate mood stabilization.

Rationale for Tapering Escitalopram Before Bupropion

Risk Profile in Bipolar Disorder

SSRIs like escitalopram carry a higher risk of inducing mood destabilization and manic episodes in bipolar I disorder compared to bupropion 1. The guidelines explicitly warn that "antidepressants may destabilize the patient's mood or incite a manic episode" and note that "manic symptoms associated with an SSRI may represent the unmasking of the disorder or disinhibition secondary to the agent" 1.

The WHO guidelines specifically recommend that "selective serotonin reuptake inhibitors (SSRI; fluoxetine) should be preferred to tricyclic antidepressants (TCA)" when antidepressants are used, but emphasize they should "always be in combination with a mood stabilizer" 2. This suggests SSRIs are considered higher-risk agents that require careful monitoring.

Evidence Supporting Bupropion's Relative Safety

While both antidepressants pose risks in bipolar disorder, the ISBD task force consensus indicates that "serotonin reuptake inhibitors and bupropion may have lower rates of manic switch than tricyclic and tetracyclic antidepressants" 3. However, among these lower-risk options, bupropion has a distinct mechanism (norepinephrine-dopamine reuptake inhibitor) that may offer some advantages in bipolar patients who still require antidepressant augmentation.

Current Mood Stabilization Status

This patient is already on a robust mood stabilization regimen with three agents (quetiapine, lithium, and lamotrigine). The patient is described as "stable," suggesting the current depressive symptoms are controlled. Guidelines emphasize that "antidepressants should be prescribed only as an adjunct to mood-stabilizing medications" 3, and with three mood stabilizers on board, the need for dual antidepressant therapy is questionable.

Clinical Algorithm for Antidepressant Tapering

Step 1: Assess Current Mood State

• Confirm patient has been stable (no depressive or manic symptoms) for at least 2-3 months
• Verify therapeutic levels of lithium (if monitored)
• Ensure no recent stressors or life changes

Step 2: Taper Escitalopram First

• Reduce escitalopram by 25-50% every 1-2 weeks to minimize discontinuation syndrome 4
• Monitor closely for:
  • Return of depressive symptoms
  • Emergence of hypomanic/manic symptoms
  • SSRI discontinuation syndrome (dizziness, paresthesias, anxiety)

Step 3: Observation Period

• Maintain bupropion and all mood stabilizers for 2-3 months after escitalopram discontinuation
• If patient remains stable, consider whether bupropion taper is indicated

Step 4: Consider Bupropion Taper (if indicated)

• Only proceed if patient has been stable off escitalopram for several months
• Taper bupropion gradually over 2-4 weeks
• Continue indefinite maintenance with quetiapine, lithium, and lamotrigine 2

Important Caveats and Pitfalls

Avoid abrupt discontinuation: Both SSRIs and bupropion should be tapered gradually. SSRIs in particular can cause significant discontinuation syndromes 4.

Monitor for treatment-emergent mania: The period during and after antidepressant taper can paradoxically trigger mood episodes. Weekly monitoring for the first month is prudent.

Maintain mood stabilizers: The guidelines emphasize that "maintenance treatment should continue for at least 2 years after the last episode of bipolar disorder" 2. Do not reduce quetiapine, lithium, or lamotrigine during antidepressant tapers.

Consider why two antidepressants were prescribed: If the patient required dual antidepressant therapy to achieve stability, this suggests treatment-resistant depression. In such cases, consultation with a psychiatrist before tapering is advisable, and alternative strategies (such as optimizing mood stabilizer doses) should be considered.

Bipolar I vs. II distinction matters: The evidence suggests "the frequency and severity of antidepressant-associated mood elevations appear to be greater in bipolar I than bipolar II disorder" 3. Since this patient has bipolar I disorder, the urgency to reduce antidepressant burden is higher.

Long-term antidepressant use controversy: The ISBD task force noted "striking incongruity between the wide use of and the weak evidence base for the efficacy and safety of antidepressant drugs in bipolar disorder" 3. In a stable patient on adequate mood stabilizers, reducing antidepressant exposure aligns with evidence-based practice.